Studies have shown that lesions with higher numbers of CD8+ TILs tend to be more sensitive to ICIs [8,9], and there is mounting evidence supporting the clinical utility of CD8+ TILs as a biomarker in various cancers [10,11,12,13,14,15]. Here, CD8A is linked to cancer.